Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C9H15NO3S |
Molecular Weight | 217.285 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](CS)C(=O)N1CCC[C@H]1C(O)=O
InChI
InChIKey=FAKRSMQSSFJEIM-BQBZGAKWSA-N
InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7-/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/11026653Curator's Comment: The description was created based on several sources, including
http://www.nevapress.com/cdr/full/17/2/115.pdf | https://www.ncbi.nlm.nih.gov/pubmed/8138187
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11026653
Curator's Comment: The description was created based on several sources, including
http://www.nevapress.com/cdr/full/17/2/115.pdf | https://www.ncbi.nlm.nih.gov/pubmed/8138187
Epicaptopril is an impurity of Captopril, which is an orally active angiotensin-converting enzyme (ACE) inhibitor used in the treatment of hypertension and congestive heart failure. Epicaptopril does not show any inhibition of angiotensin-converting enzyme (ACE), and can be used as negative control in ACE inhibition experiments
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11026653
Rats: 5 mg/kg twice daily for 10 days, per os.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.nevapress.com/cdr/full/17/2/115.pdf
The protective effects of SH-ACEIs from free radical-induced cell damage have been also assessed in cultured endothelial cells exposed to a superoxide anion and hydroxyl radicals generating system. Preincubation of the cells with captopril, epicaptopril, or zofenopril produced a concentration-dependent (10–200 mkM) inhibition of malonyldialdehyde formation. Both loss of cell viability and membrane blebbing were reduced by SH-ACEIs at concentrations as low as 10 mkM. In contrast, lisinopril and enalaprilat at concentrations up to 200 mkM were ineffective
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
63250-36-2
Created by
admin on Sat Dec 16 01:39:09 GMT 2023 , Edited by admin on Sat Dec 16 01:39:09 GMT 2023
|
PRIMARY | |||
|
DB02032
Created by
admin on Sat Dec 16 01:39:09 GMT 2023 , Edited by admin on Sat Dec 16 01:39:09 GMT 2023
|
PRIMARY | |||
|
688267
Created by
admin on Sat Dec 16 01:39:09 GMT 2023 , Edited by admin on Sat Dec 16 01:39:09 GMT 2023
|
PRIMARY | |||
|
DTXSID60212642
Created by
admin on Sat Dec 16 01:39:09 GMT 2023 , Edited by admin on Sat Dec 16 01:39:09 GMT 2023
|
PRIMARY | |||
|
PPW0ENH1HA
Created by
admin on Sat Dec 16 01:39:09 GMT 2023 , Edited by admin on Sat Dec 16 01:39:09 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD